Last reviewed · How we verify
Hemay005 tablets
At a glance
| Generic name | Hemay005 tablets |
|---|---|
| Also known as | Hemay005 45 mg BID group, Hemay005 placebo BID group |
| Sponsor | Ganzhou Hemay Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD (PHASE2)
- Evaluation the Safety of hemay005 Tablets (PHASE1)
- To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage (PHASE1)
- To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment (PHASE1)
- Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets (PHASE1)
- A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease (PHASE3)
- Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis (PHASE2)
- Bioequivalence Test of Hemay005 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemay005 tablets CI brief — competitive landscape report
- Hemay005 tablets updates RSS · CI watch RSS
- Ganzhou Hemay Pharmaceutical Co., Ltd portfolio CI